Citi placed an “upside 90-day catalyst watch” on Ideaya Biosciences (IDYA) while keeping a Buy rating on the shares with a $64 price target The firm likes the share setup into the Phase 2/3 OptimUM-02 trial data, expected in Q1, for metastatic uveal melanoma.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences completes enrollment in OptimUM-02 trial
- IDEAYA Biosciences: Promising Future with Innovative Dual KAT6/7 Inhibitor and Strong Financial Position
- Ideaya Biosciences submits IDE574 IND application to FDA
- Ideaya financials not impacted by GSK termination, says Mizuho
- Ideaya disclosed termination of GSK license agreement